{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is defined as \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28; with Lenalidomide 25 mg (10 mg if Estimated Glomerular Filtration (eGFR) is 40-60 milliLitre (mL)/minute/1.73 square meter (m)\\^2) administered orally once daily (QD) from Day 1 to Day 21; and Dexamethasone 40 mg (20 mg for participants \\>75 years old or BMI \\<18.5 kg/m\\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone"},{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.0 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution infused over 30- 60 minutes Q4W for cycle 1 and then Q8W for cycle 2 onwards on day 1 of 28-day cycle in Q4W and 56-day cycle in Q8W in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28; with Lenalidomide 25 mg (10 mg if Estimated Glomerular Filtration (eGFR) is 40-60 milliLitre (mL)/minute/1.73 square meter (m)\\^2) administered orally once daily (QD) from Day 1 to Day 21; and Dexamethasone 40 mg (20 mg for participants \\>75 years old or BMI \\<18.5 kg/m\\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG001","title":"1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone"}],"populationDescription":"No participants were enrolled as CE Phase was not initiated due to business strategic reason.","reportingStatus":"POSTED","timeFrame":"Up to 143 weeks","title":"CE Phase: Clinical Benefit Rate (CBR)","type":"SECONDARY"}